RxDoctor Payments Data

Justin Stenquist, MD

Family Medicine · Mesa, AZNPI 1285096503

Payments from drug & device makers

$7,314in general payments, 2019–2025

Across 428 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$530
  • GSK$490
  • Amgen$468
  • Bayer$465
  • Abbott$440
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,314 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$93,170
Medicare patients
164
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$109,908
MounjaroTirzepatide49$73,076
EliquisApixaban39$51,293
OzempicSemaglutide28$50,836
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$31,403
Soliqua 100-33Insulin Glargine/Lixisenatide40$31,261
TrulicityDulaglutide16$24,580
XareltoRivaroxaban17$24,337
VraylarCariprazine Hcl14$23,573
JanuviaSitagliptin Phosphate21$21,316
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$21,022
MyrbetriqMirabegron21$14,600
Spiriva RespimatTiotropium Bromide11$7,961
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,646
LinzessLinaclotide11$6,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$295$117,86993 claims
Lilly USA, LLCMounjaro, Trulicity$423$97,65565 claims
PfizerEliquis$437$51,29339 claims
Novo NordiskOzempic$530$50,83628 claims
GSKTrelegy Ellipta$490$31,40323 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$129$31,26140 claims
AbbVieVraylar, Linzess$1,188$30,29625 claims
Johnson & JohnsonXarelto$97$24,33717 claims
MerckJanuvia$140$21,31621 claims
Astellas Pharma US IncMyrbetriq$108$14,60021 claims
AstraZenecaSymbicort$359$4,05311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →